Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

415.21 -2.63 (-0.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
69 70 Next >
News headline image
United Therapeutics Forges Ahead with Share Repurchases, Not Dividends, Following July 2025 Volume Surge
In a financial landscape often fixated on consistent dividend payouts, United Therapeutics Corporation (NASDAQ: UTHR) stands out with a distinct capital allocation strategy. Contrary to market... 
Via MarketMinute
Topics Retirement
News headline image
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs? ↗
Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential impact on Eli Lilly and Pfizer. 
Via Benzinga
Topics Government
News headline image
Marjorie Taylor Greene, Cathie Wood Snap Up The Same 13 Stocks — Here's the Unlikely Portfolio Crossover ↗
A look at the stock owned by both Ark Funds and Congresswoman Marjorie Taylor Greene. 
Via Benzinga
News headline image
P/E Ratio Insights for Amgen ↗
 
Via Benzinga
News headline image
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity ↗
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline. 
Via Benzinga
News headline image
Dow Jones Stumbles with Fractional Dip, Signaling Cautious Market Sentiment Amidst Global Headwinds
New York, NY – October 15, 2025 – The Dow Jones Industrial Average (DJIA) experienced a fractional dip today, reflecting a palpable sense of caution pervading market sentiment. While other major... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Reflecting On Therapeutics Stocks’ Q2 Earnings: Amgen (NASDAQ:AMGN)
Looking back on therapeutics stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Amgen (NASDAQ:AMGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Trump Plans AstraZeneca Deal To Cut Drug Prices For Low-Income Americans ↗
Trump to announce new deal with AstraZeneca to lower prescription drug costs for Americans using most-favored-nation pricing model. 
Via Benzinga
Topics Government
News headline image
Trump Administration Engages Pharmacies, GoodRx For TrumpRx Launch ↗
Pharmacies and GoodRx are in talks to join TrumpRx, a new drug pricing site aiming to lower prescription costs for U.S. consumers. 
Via Benzinga
Topics Government
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
2 S&P 500 Stocks to Target This Week and 1 Facing Challenges
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
News headline image
Martin Capital Buys Into Portland General Electric’s Defensive Power Play ↗
Via The Motley Fool
Topics Energy Regulatory Compliance
News headline image
Amgen To Offer Cholesterol Drug At 60% Discount As Trump Administration's Call To Lower Drug Prices ↗
Amgen launches AmgenNow, offering Repatha at $239 per month, expanding direct access for U.S. patients with no insurer restrictions. 
Via Benzinga
Topics Government
News headline image
Martin Capital Dumps $3.0 Million Worth of LyondellBasell Industries Stock ↗
Via The Motley Fool
Topics Energy
News headline image
Martin Capital Liquidates its Diageo Position: What That Means for the Alcoholic Beverages Titan ↗
Via The Motley Fool
News headline image
Martin Capital Exits $5.8 Million Comcast Stake as Broadband Challenges Persist ↗
Via The Motley Fool
News headline image
Martin Capital Sells $3.6 Million in JPMorgan Stock — What to Know Ahead of Q3 Earnings ↗
Via The Motley Fool
News headline image
Amgen To Sell Cholesterol Drug For Approximately 60% Discount ↗
Patients can purchase Repatha at a discount through Amgen’s direct-to-patient program, AmgenNow. 
Via Stocktwits
Topics Government
News headline image
4 Reasons to Buy Amgen Stock Right Now ↗
For those with a sufficiently long investment horizon, the stock looks attractive. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Wall Street Hits Record Highs As Rate Cut Bets Offset Shutdown: This Week In Markets ↗
S&P500, Nasdaq100, Dow Jones, and Russell 2000 all hit record highs as investors focus on corporate optimism, monetary easing and AI tech. 
Via Benzinga
Topics Artificial Intelligence Stocks
News headline image
FDA Greenlights Jazz and Roche's Zepzelca-Tecentriq for ES-SCLC Maintenance, Reshaping Lung Cancer Treatment Landscape
In a pivotal moment for oncology, the U.S. Food and Drug Administration (FDA) on October 2, 2025, granted approval for the innovative combination of Jazz Pharmaceuticals' (NASDAQ: JAZZ) Zepzelca... 
Via MarketMinute
News headline image
U.S. Jobs Report Stalled Amidst Federal Shutdown: A Critical Information Vacuum for Markets and Policymakers
Washington D.C., October 2, 2025 – As a federal government shutdown extends into its second day, the highly anticipated U.S. Jobs Report, typically released on the first Friday of each month, has been... 
Via MarketMinute
Topics Bonds Economy
News headline image
Healthcare Sector Shines Amidst Market Turbulence, Bolstering S&P 500 Resilience
On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Novo Nordisk (NVO) Soars as HSBC Upgrades to "Buy," Citing Strategic Focus and Pipeline Strength
Copenhagen, Denmark – October 2, 2025 – Shares of Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) experienced a significant surge yesterday, October 1, 2025, following a pivotal upgrade from HSBC.... 
Via MarketMinute
Topics Economy
News headline image
These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheap ↗
Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount. 
Via Benzinga
News headline image
Amgen Surges on Repatha Expansion, Manufacturing Boost, and Strong Earnings
Thousand Oaks, CA – October 2, 2025 – Amgen (NASDAQ: AMGN) has witnessed a robust surge in its share price, climbing approximately 6% in recent trading sessions, culminating on October 2, 2025, to... 
Via MarketMinute
Topics Economy Intellectual Property Stocks
News headline image
Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Stocks making big moves yesterday: ZoomInfo, Dave, Atkore, Saia, and Amgen
Check out the companies making headlines yesterday: 
Via StockStory
News headline image
Bruce Beutler Unlocked Key Mystery To Disease — And He's Not Done ↗
What's one piece of advice Dr. Bruce Beutler gives to anyone interested in excelling in science? Go outside. It worked for him. 
Via Investor's Business Daily
News headline image
2 High-Yield Dividend Growth Stocks to Buy in October and Hold for a Decade or Longer ↗
These stocks have been raising their payouts much faster than most dividend payers. 
Via The Motley Fool
Topics Economy
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
69 70 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.